Evidence map›Paper›PMID 41172985›Full record

ArticleCell host & microbe2025

Bioengineered gut bacterium synthesizing levodopa alleviates motor deficits in models of Parkinson's disease.

Piyush Padhi, Ahmed Abdalla, Benjamin Schneider, Nick Backes, Alyssa A Otto, Ileia J Scheibe, Jacob P Thomas, Gargi Khadse, Manikandan Samidurai, Alexander K Jochmans and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell host & microbe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Genome-integrated engineering ofSynthetic and systems biotechnology · 2027
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Piyush PadhiIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Ahmed AbdallaDepartment of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
Benjamin SchneiderDepartment of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
Nick BackesVeterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
Alyssa A OttoIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA.
Ileia J ScheibeIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA.
Jacob P ThomasIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA.
Gargi KhadseIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA.
Manikandan SamiduraiIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA.
Alexander K JochmansIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Amanda GeorgeIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA.
Gary ZenitskyIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Huajun JinIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Vellareddy AnantharamIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Arthi KanthasamyIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Aditya MishraDepartment of Statistics, Franklin College of Arts and Sciences, University of Georgia, Athens, GA 30602, USA.
Karin AllenspachDepartment of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Jonathan MochelDepartment of Pathology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Gregory J PhillipsIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.
Anumantha G KanthasamyIsakson Center for Neurological Disease Research, University of Georgia, Athens, GA 30602, USA; Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA. Electronic address: anumantha.kanthasamy@uga.edu.

Funding

Novel Reengineered Microbiome-based Biologic Therapy to Treat Cognitive and Behavioral Symptoms of Alzheimer's Disease and Related DementiasU01AG074960 · NIA · UNIVERSITY OF GEORGIA · PI Anumantha Gounder Kanthasamy, James Gregory PHILLIPS · 2022 to 2026
$7.4M
Novel Re-engineered L DOPA Probiotic Therapy for Parkinson's DiseaseR33NS112441 · NINDS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2022 to 2023
$765k
Novel Re-engineered L DOPA probiotic therapy for Parkinsons DiseaseR61NS112441 · NINDS · UNIVERSITY OF GEORGIA · PI KANTHASAMY, ANUMANTHA GOUNDER · 2020 to 2020
$387k
NIA NIH HHS U01 AG074960NINDS NIH HHS R33 NS112441NINDS NIH HHS R61 NS112441
6 · The paper itself

Abstract

L-3,4-Dihydroxyphenylalanine (L-DOPA), synthesized from L-tyrosine, is a direct precursor to dopamine. L-DOPA is the gold-standard treatment for Parkinson's disease (PD), given orally alongside decarboxylase inhibitors (e.g., benserazide) to enhance bioavailability. However, its chronic daily pulsatile-like delivery is associated with complications. Herein, we show the construction and in vivo efficacy of a programmable, titratable, genetically engineered E. coli Nissle 1917 system (EcN

Indexed as

Antiparkinson AgentsEscherichia coliGastrointestinal MicrobiomeLevodopaParkinson DiseaseAdministration, OralAnimalsBenserazideBrainDisease Models, AnimalDogsDopamineHumansMiceTyrosineAntiparkinson AgentsBenserazideDopamineLevodopaTyrosinebacterial therapeuticsCanine modeldrug deliveryE. coli Nissle 1917engineered live biotherapeuticsgut microbiomelevodopaMitoParkParkinson’s diseasesynthetic biology

Identifiers

PMID41172985
PMCPMC12671020

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.